SELLAS Life Sciences nears final analysis in pivotal Phase 3 REGAL AML trial
SELLAS Life Sciences nears final analysis in pivotal Phase 3 REGAL AML trial as Q1 2026 EPS beats estimates
- Pivotal Phase 3 REGAL AML trial has reached 78 of 80 events required for final analysis.
- Reported fiscal Q1 2026 non-GAAP EPS $-0.05, improving 29% YoY, on revenue $0, beating EPS estimates.
- Q1 2026 results highlight $107.1 million in cash plus $7.5 million raised from warrant exercises.
- Company establishes $150 million ATM equity offering program as part of its Q1 2026 update.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.